Prediction of MGMT Status for Glioblastoma Patients Using Radiomics Feature Extraction From ¹⁸F-DOPA-PET Imaging.

ABSTRACT:

Purpose

Methylation of the O⁶-methylguanine methyltransferase (MGMT) gene promoter is associated with improved treatment response and survival in patients with glioblastoma (GB), but the necessary pathologic specimen can be nondiagnostic. In this study, we assessed whether radiomics features from pretreatment ¹⁸F-DOPA positron emission tomography (PET) imaging could be used to predict pathologic MGMT status.

Methods and materials

This study included 86 patients with newly diagnosed GB, split into 3 groups (training, validating, and predicting). We performed a radiomics analysis on ¹⁸F-DOPA PET images by extracting features from 2 tumor-based contours: a "Gold" contour of all abnormal uptake per expert nuclear medicine physician and a high-gra

SUBMITTER: Qian J 

PROVIDER: S-EPMC7680434 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature